Cancer
01 Jan 2013
Treatment Stratification According to Early Response to Mega-CHOP
Aim: To assess the efficacy of PBSCT in patients with poor prognosis aggressive NHL according to previous early response to Mega-CHOP evaluated with CT & Ga67S. Those in CR (CT scan, Ga67S negative) or uCR (CT scan positive, Ga67S negative) received a 4th Mega-CHOP followed by BEAM and PBSCT. Those…
Cancer
01 Jan 2013
Factors Affecting HD pts treated with IEGV and HDT with stem cell rescue
Aim: To identify prognostic factors in patients with relapsing/refractory Hodgkin’s Disease treated with IGEV Chemotherapy and High Dose Consolidation Therapy. Conclusions: Based on this analysis, a prognostic model for IGEV-treated patients with refractory/relapsed HD can be constructed using the above factors. Official Title Factors Affecting Outcome of Patients with Refractory/Relapsed…
Cancer
01 Jan 2013
R-GIFOX for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma
Aim: To evaluate the clinical activity, toxicity and mobilizing capacity of a new short-course (bi-weekly), dose intensive, cytoreductive/mobilizing salvage regimen (R-GIFOX) combining the cross-synergistic agents Gemcitabine (G), Ifosfamide (Ifo), Oxaliplatin (Ox) and Rituximab (R) in patients with relapsed and refractory CD20+ NHL. Conclusions: R-GIFOX was feasible, tolerable, effective…
Blood
01 Jan 2013
Comparison between Cy then G-CSF and IVE Plus G-CSF in Haematological Malignancies
Aim: To retrospectively compare the PBPC yields of harvests after IVE with those of standard Cy/G-CSF priming. Conclusions: Priming with IVE yields higher PBPC numbers than cyclophosphamide, patients requiring fewer pheresis, therefore reducing the cost. Official Title A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and…
Cancer
01 Jan 2013
Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI
Aim: To explore a more effective treatment for newly-diagnosed localized nasal NK/T-cell lymphoma, we conducted a multicenter phase I/II study of concurrent chemoradiotherapy. Conclusions: Researchers concluded results suggest that concurrent chemoradiotherapy using MDR- non-related agents and ETP is a promising treatment strategy for localized nasal NK/T-cell…
Cancer
01 Jan 2013
HD Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin’s Lymphoma
Aim: Prior studies showed that overexpression of bcl-2 and p53 have negative impact on outcome with primary therapy. The study sought to determine if the comprehensive second-line program could overcome these poor prognostic features. Conclusions: Researchers concluded that despite the evidence that p53 and bcl-2 overexpression may predict…
Cancer
01 Jan 2013
The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL)
Aim: To improve progression-free survival (PFS) in MCL using a strategy of incorporating approaches of intensifying induction & intensifying consolidation with high dose chemo radiotherapy (HDT by administering an anthracycline-containing regimen in a dose dense fashion CHOP- or R-CHOP-14) followed by consolidation with ICE HDT/ASCT. Conclusions: Researchers…
Cancer
01 Jan 2013
An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation
Aim: To assess efficacy and toxicity of 2 and 3 drug salvage regimens. Conclusions: Researchers concluded that both VGF and F-GIV can be safely administered on an outpatient basis and show activity against advanced lymphoma Official Title Conditions Study Type Phase II Study Design Patients were stratified into:…
Cancer
01 Jan 2013
RADAR Trial – Randomised Androgen Deprivation and Radiotherapy
Purpose The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen deprivation prior to and during radiotherapy; 2) that 18 months Bisphosphonate therapy will prevent bone loss caused by androgen deprivation…
